Duchenne muscular dystrophy: News & Analysis

Coverage of "Duchenne muscular dystrophy" on Cryptosearcher: the stories and the context behind them.

Capricor Therapeutics Faces Sharp 70% Stock Drop Amid FDA Doubts on Cell Therapy Data

Capricor Therapeutics' shares dropped 70% after the FDA questioned the validity of their cell therapy trial data and changes made post-study. The upcoming advisory committee meeting could decide the therapy’s fate.

July 27, 2026

Capricor Therapeutics Faces Sharp 70% Stock Drop Amid FDA Doubts on Cell Therapy Data